SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " regulator " 672 found 🔀 AI-powered Shuffle
Uber Doubles Down on Türkiye with Agreement to Acquire Getir’s Delivery Business
ISTANBUL, February 09, 2026--Uber Technologies, Inc. (NYSE: UBER) and Mubadala Investment Company today announced an agreement for Uber to acquire Getir’s delivery portfolio in Türkiye, including food, grocery, retail, and water delivery, subject to regulatory approval and other closing conditions.
Regulating Digital Health Technologies
Randi Seigel examines the evolving regulatory landscape for digital health tools.
Hims & Hers responds to FDA pressure, pulls knockoff Wegovy drug launch after regulatory threats
Telehealth company Hims & Hers cancels $49 monthly weight loss drug launch following FDA warnings about unapproved semaglutide compounds and Novo threats.
Health Regulators Ask DOJ to Investigate Hims & Hers. The Stock Plunges.
The Department of Health and Human Services referred the consumer wellness company to the Department of Justice for investigation, wrote HHS general counsel Mike Stuart in a post on X Friday afternoon.
Why colorectal cancer breaks the immune system’s rules
Colorectal cancer has long baffled scientists because, unlike most tumors, patients often do better when their cancers are packed with immune-suppressing regulatory T cells. New research finally explains why. Scientists discovered that these T cells aren’t all the same: one subtype actually helps keep tumors in check, while another shields cancer from immune attack. The balance between these “good” and “bad” cells can determine whether a tumor grows or shrinks.
China Consumer Loyalty Business Report 2026: A $35.65 Billion Market by 2030 from $18.46 Billion in 2025 - 88VIP, JD.com, Meituan Black Card, and WeChat Infrastructure Anchor Platform-Led Models
The Chinese loyalty market presents prime opportunities in embedded, platform-driven loyalty models and membership-based systems across various sectors. Integration into super-app ecosystems, leveraging data-driven personalization within regulatory constraints, and blending offline-to-online experiences are key growth avenues. Chinese Loyalty Market Chinese Loyalty Market Dublin, Feb. 06, 2026 (GLOBE NEWSWIRE) -- The "China Loyalty Market Size & Forecast by Spend Value Across 100+ KPIs by Progra
Second House panel warms to Chase Tramont bill on heated tobacco regulatory change
The measure would establish a different taxing structure for heated tobacco products, which are considered a less harmful alternative to cigarettes.
Bondi Junction stabbings: Doctor of killer referred to health regulators
A coroner has found Joel Cauchi's doctor failed to heed warnings he was having a relapse of schizophrenia.
HCPro Joins National Cooperative of Health Networks to Support Rural Healthcare Workforce Development
Chicago, IL, Feb. 04, 2026 (GLOBE NEWSWIRE) -- HCPro, a leading provider of healthcare education and regulatory solutions, today announced its partnership with the National Cooperative of Health Networks Association (NCHN), reinforcing HCPro’s commitment to supporting rural and community healthcare organizations through practical, role-based workforce education. As a partner of NCHN, HCPro will contribute expertise and resources to help rural health leaders address ongoing workforce challenges,
Everbridge Recognized in Business Continuity Management Software Landscape, Q1 2026 Report by Independent Research Firm
VIENNA, Va., February 04, 2026--Everbridge, Inc., the global leader in High Velocity Critical Event Management (CEM) and national public warning solutions, today announced its inclusion in Forrester’s The Business Continuity Management Software Landscape, Q1 2026. The report reflects renewed urgency around business continuity as organizations face more frequent disruptions, rising operational risk, and expanding regulatory expectations tied to resilience and preparedness – areas Everbridge suppo
Johns Hopkins Health Plans Executive Elected Chair of Medicare Advantage Plan Alliance Compliance Forum
Melissa Mohon to Lead National Organization Dedicated to Improving Regulatory Compliance and Quality Care for Medicare BeneficiariesHANOVER, Md., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Melissa L. Mohon, Executive Director of Compliance, Privacy and Regulatory Affairs at Johns Hopkins Health Plans, has been elected Chair of the Medicare Advantage Plan Alliance (MAPA) Compliance Forum. In this role, Mohon will lead the national organization’s efforts to advance regulatory compliance and strengthen coll
CVS Health Faces Antitrust Scrutiny As Valuation Flags Undervaluation Risk
U.S. House Judiciary Committee alleges CVS Health restricted independent pharmacies from using competing digital pharmacy hubs. The investigation cites cease and desist letters and network rule changes as potential antitrust issues. CVS Health disputes the findings and says some policies have been revised. For investors watching CVS Health (NYSE:CVS), the focus is shifting to regulatory risk around how its pharmacy network operates. The company’s shares closed at $74.52, with a return of...
Pace(R) Earns Environmental Business Journal Award for Adding Respirable Crystalline Silica Testing
Company awarded Business Achievement Award for New Practice in 2025 MINNEAPOLIS, MINNESOTA / ACCESS Newswire / January 30, 2026 / Pace® Analytical Services, the preferred provider of regulatory testing and analytical laboratory services, and a Division ...
Predictions market regulator scraps proposed ban on sports contracts, says new rules are coming
Contracts on live sports offered by Kalshi, Polymarket and others have drawn comparisons to the wave of legalized sports betting in the U.S.
cbdMD Strengthens Regulatory Science Platform to Support Emerging Regulatory Cannabinoid Evaluation Pathways
cbdMD, Inc. (NYSE American: YCBD), a leading innovator in hemp-derived wellness products, today announced a strategic initiative to integrate and expand its regulatory science, safety, and intellectual property assets to establish a differentiated cannabinoid compliance and evidence platform aligned with evolving federal healthcare evaluation frameworks, including emerging CMS and CMMI innovation initiatives.
California mental health hospitals warn over cuts after state hands down staffing rules
Psychiatric hospitals could close beds under proposed state rules if regulators don’t allow implementation time, facilities warn.
An ousted energy regulator reflects on Georgia’s new power politics
Former utility commissioner Tim Echols talks climate change, the Republican party, and how the state will deal with rising power demand.
Chinese-made teething toys sold on Amazon recalled over fatal choking risk
Federal regulators announced the recall of Yetonamr pull-string teething toys manufactured in China after 32 reported choking incidents, urging parents to immediately destroy products.
A Look At Flutter Entertainment’s Valuation As Downgrades And UK Regulatory Shifts Weigh On Sentiment
Why Flutter Entertainment’s boardroom and regulatory news matters for shareholders Flutter Entertainment (FLUT) has been under pressure recently, with the stock down about 20% over the past month and roughly 28% over the past 3 months, against a backdrop of changing analyst sentiment. Several banks and brokers have reassessed their views, with a string of downgrades and lower price targets highlighting concerns around short term headwinds. At the same time, UK regulatory developments and a...
CVS Health (CVS) Valuation Check As Regulatory Scrutiny And Legal Outcomes Draw Investor Focus
Regulatory and legal scrutiny is back in focus for CVS Health (CVS), as a U.S. House Judiciary Committee probe into its pharmacy benefit manager practices unfolds, while a separate class action over prescription drug pricing has been dismissed. See our latest analysis for CVS Health. For context, CVS Health shares now trade at US$82.68, with a 30 day share price return of 5.95% and a year to date share price return of 3.18%, while the 1 year total shareholder return of 59.48% reflects how...
These 3 Policy Moves Are Likely To Change Health Care for Older People
Two Trump administration regulatory rollbacks affect nursing home staffing and home care workers, and a new AI experiment in Medicare has alarmed eldercare advocates and congressional Democrats.
Ken Griffin says Biden-era regulations ‘exhausting’ on American businesses, 'cost the US economy dearly'
Citadel CEO Ken Griffin says Biden administration's regulatory policies created 'constant friction' for businesses, calling Trump's approach an 'extraordinary boom.'
Gov. Tina Kotek has a plan to boost Oregon businesses, but challenges remain steep
Lawmakers and business leaders in Oregon have argued the state's tax and regulatory landscape is too harsh for businesses. Gov. Tina Kotek has signaled she wants to change Oregon's business reputation.
Kalshi cannot operate sports-prediction market in Massachusetts, judge rules
A Massachusetts judge on Tuesday ruled prediction-markets operator Kalshi cannot let state residents bet on sports through its online platform, after the state's attorney general accused it of running afoul of gaming regulators.
Britain to review historic antitrust remedies to ease business burden
Britain's antitrust regulator said on Monday it would review its historical interventions in markets to check they were still necessary, and if not it would remove them to ease the burden of compliance for businesses.
Scientists find ‘master regulator’ that could reverse brain aging
Researchers have identified OTULIN, an immune-regulating enzyme, as a key trigger of tau buildup in the brain. When OTULIN was disabled, tau vanished from neurons and brain cells remained healthy. The findings challenge long-held assumptions about tau’s necessity and highlight a promising new path for fighting Alzheimer’s and brain aging. Scientists now believe OTULIN may act as a master switch for inflammation and age-related brain decline.
Sponsored: For Louisiana’s Menhaden Fishery, If Science Doesn’t Guide Regulations, What Does?
Louisiana has long relied on science to guide how it manages its natural resources. From energy to agriculture to fisheries, legislators and regulators have invested in research, monitoring, and expert
3 Policy Moves Likely to Change Health Care for Older People
Two regulatory rollbacks, along with a new A.I. experiment in Medicare, raise some worrisome questions.
UK health regulator approves up to 7.2 mg weekly dose of Wegovy for obesity patients
Britain's health regulator approved a maximum dose of up to 7.2 miligrams per week of Novo Nordisk's blockbuster weight-loss drug Wegovy for patients with obesity only, it said on Friday.
NCAA asks CFTC to suspend prediction markets
The NCAA asked a federal regulatory body to stop prediction markets from offering trades on college sports until more safeguards are in place.
Prof. Dorit Reiss Wins National Award for Distinguished Service in Health Law - UC Law San Francisco (Formerly UC Hastings)
Professor Dorit Reiss, who brings legal expertise to public health debates, has received a national award for her lasting contributions to the field as a scholar, policy adviser, and mentor. Faculty Who Lead: Dorit Reiss Professor Dorit Reiss receives the 2026 Distinguished Service Award from the AALS Section on Law, Medicine and Health Care. She is a leading expert on vaccine law, advising policymakers and providing expert analysis to journalists. Reiss mentors future health law scholars and combats misinformation online through evidence-based public education. Professor Dorit Reiss, a leading voice on vaccine law and policy, has won a national award recognizing her contributions to health law. She received the 2026 Distinguished Service Award from the Association of American Law Schools (AALS) Section on Law, Medicine and Health Care. Presented at the AALS Annual Meeting in January, the award honors sustained service to public health and the health law academy through advocacy, public education, and mentorship. In presenting the award, Professor Doron Dorfman of Seton Hall Law School, chair-elect of the AALS Section on Law, Medicine and Health Care, described Reiss as “a committed public health advocate who has used her expertise to influence vaccine policy, research, and practice at both the state and federal levels for nearly two decades.” Reiss leads a widely read vaccine law listserv that provides real-time updates on litigation, regulatory developments, advisory committee proceedings, and public comment opportunities. The resource has become an important tool for lawyers, scholars, journalists, and public health professionals tracking fast-moving developments in vaccine policy. Her service extends to policymaking as well. She has supported vaccine-related legislation in California, testified before the U.S. Senate Judiciary Committee on vaccine mandates and non-medical exemptions, and serves on the Parent Advisory Board of Voices for Vaccines, a parent-led organization focused on reducing vaccine-preventable disease. Dorfman also highlighted Reiss’ active role in robust debates over vaccine safety and related laws and policies. “She directly engages misinformation by responding to anti-vaccination claims on social media with careful, evidence-based rebuttals,” Dorfman said. As federal vaccine policy undergoes significant change, Reiss has become a trusted source for major national news outlets, including The New York Times, The Washington Post, and CNN, which regularly seek her expert analysis on new policies and decisions. Dorfman noted that Reiss is widely respected for her mentorship of health law faculty and scholars. “She is consistently generous with her time—approachable, willing to provide feedback, and a mentor to many in the field, including myself,” he said. At UC Law SF, Reiss brings the spirit of public service into the classroom, helping students understand how legal frameworks translate into real-world public health outcomes. She holds the James Edgar Hervey ’50 Chair of Litigation, a position that recognizes faculty excellence in the field of litigation. The Distinguished Service Award highlights her sustained commitment to evidence-based vaccine policy, public education, and mentorship during a pivotal time for public health law.
Pazdur warns that politics, ‘chaos’ are damaging FDA
At a STAT event, veteran drug regulator Richard Pazdur, who left the FDA last month after 26 years, said that politics and 'chaos' were damaging the agency.
New liquor rules reshape N.Y. nightlife and businesses
New liquor rules will let more venues across the state serve drinks and give bars extra flexibility, while regulators stress safety.
HTI 5 Proposal Signals Health IT Deregulation and FHIR-first Interoperability and Refines Information Blocking Rule
The new Health Data, Technology and Interoperability proposed rule (known as HTI-5) signals a significant deregulatory shift aimed at...
Texas health regulators propose major fee hikes, new rules for hemp-derived THC products
Texas health regulators are considering sweeping changes that could dramatically reshape the hemp-derived THC industry, and many small business owners say the cost alone could put them out of business.
Doseology Engages McKinney Regulatory Science Advisors to Advance Innovative Oral Pouch Product Development through Science and Regulatory Expertise
Doseology Sciences Inc. (CSE: MOOD) (PINK: DOSEF) (FSE: VU70) ("Doseology" or the "Company") a leader in biotechnology-driven consumer products, today announced a strategic partnership with McKinney Regulatory Science Advisors ("McKinney"), a premier FDA regulatory consulting firm specializing in nicotine and reduced-risk consumer products, to spearhead its regulatory submission strategy and solidify its commitment to scientific leadership in the oral pouch technology space.
Advancing Claude in healthcare and the life sciences
Introducing Claude for Healthcare with HIPAA-ready infrastructure, plus expanded Life Sciences tools for clinical trials and regulatory submissions. New connectors to CMS, Medidata, and ClinicalTrials.gov.
Advancing Claude in healthcare and the life sciences
Introducing Claude for Healthcare with HIPAA-ready infrastructure, plus expanded Life Sciences tools for clinical trials and regulatory submissions. New connectors to CMS, Medidata, and ClinicalTrials.gov.
Top 10 African countries with the most business-friendly environments in 2025
Rwanda, Morocco, Mauritius, and seven other African countries emerged as the continent’s top performers in the 2025 World Bank business environment rankings, demonstrating notable progress in regulatory reforms, operational efficiency, and governance
Real Chemistry Establishes RC Resolve, an Advisory Practice for Healthcare’s Most Critical Business, Regulatory and Value Inflection Points
NEW YORK, January 09, 2026--Real Chemistry launches RC Resolve, a healthcare advisory practice helping leaders navigate value inflection points.
Health district concerns mount over new chicken plant
TIFFIN — Seneca County’s health commissioner has raised concerns with state environmental regulators about a controversial livestock facility recently ...
Small Business Admin. Official Testifies on Regulatory Reform & Small Business Support
Casey Mulligan, chief counsel at the Small Business Administration's Office of Advocacy, testifies on regulatory flexibility and reform before the House Small Business Committee.
US FDA to limit regulation of health and fitness wearables, commissioner says
The U.S. Food and Drug Administration said on Tuesday that it will limit regulation of wearable devices and software designed to support healthy lifestyles, issuing new guidance to clarify its regulatory approach.
Why health care CFOs are caught between AI pressure and governance risk
A new report finds governance gaps, regulatory exposure, and thin margins are complicating AI investment decisions.
One of N.J.’s last independent hospitals to join major health chain, 3 years after failed merger with rival
The agreement still needs to go through state and regulatory approvals.
Denver Health, Children's Hospital Colorado suspend gender-affirming care for youth
In response to regulatory actions by the U.S. Department of Health and Human Services, Denver Health and Children's Hospital Colorado say they have suspended all medical gender-affirming care for patients under 18.
The business of predicting the future is booming but EU regulators remain uneasy
Prediction markets are ushering in a new era where collective judgement and "crowd wisdom" are no longer theoretical concepts but tradable commodities. Yet despite their growing success, they remain banned in many EU countries.View on euronews
The US banned a former EU official's visa over Big Tech rules — and the fight is playing out on X
The Trump administration targeted EU figures over platform regulation, triggering backlash from Macron and digital regulators.
Inside Gaming: Strip operator extending discounts into 2026
Plus, Atlantic City casinos won more than $236.8 million from gamblers in November, a year-over-year increase of 5.7 percent, according to state regulatory data.
2025 Health Care Delivery Snapshot
In 2025, MSMS advanced physician interests through advocacy, collaboration, and direct support on payer, legal, and regulatory issues. MSMS submitted letters, individually or jointly, to federal and state legislators and regulators on issues including Medicare payment, Medicaid funding, telehealth, physician-owned hospitals, downcoding policies, out-of-network care, substance use disorder home health, ACA premium tax credits, immunizations, and medical student loans. MSMS met...
Westerman’s SPEED Act accelerates to the Senate - Talk Business & Politics
U.S. Rep. Bruce Westerman, R-Hot Springs, has been working on a regulatory reform bill for years, and this week, he saw the culmination of his efforts take a giant leap...
FY26 FDA Broad Agency Announcement: Advanced Research and Development of Regulatory Science
FY26 FDA Broad Agency Announcement: Advanced Research and Development of Regulatory Science / cancer, FDA, FY26, Headlines, OncoDaily, Oncology
DraftKings backed Healey’s political nonprofit on housing. Other funders are a mystery
DraftKings, the Boston sports-betting giant, donated $50,000 to a political advocacy group launched by Gov. Maura Healey to promote housing policies. It's a rare look at who's donating to this fund, at a time when sports gambling is getting greater scrutiny from lawmakers and regulators.
Ford shows the consequences of whiplash politics
Big shifts in political power tend to lead to extreme regulatory swings, too.
Netflix CEOs Defend Warner Bros. Deal in Memo to Employees: ‘We See This as a Win for the Entertainment Industry, Not the End of It’
Ted Sarandos and Greg Peters, the co-CEOs of Netflix, issued a memo to staffers that conveyed their belief that the company's deal to buy Warner Bros. and HBO Max will withstand a counterattack by David Ellison's Paramount Skydance and will clear regulatory hurdles.
I write about ultraprocessed foods, yet I still can’t tell you how to avoid them. Here’s why
“Ultraprocessed” has become a bad word in our food supply, but regulators are struggling with how to define the term to help consumers. Here’s why that’s so hard to do.
Health and safety rules holding UK infrastructure back, says writer of government report
Exclusive: John Fingleton says regulators need to change their attitude to risk to end the country’s economic stagnation
How Investors May Respond To Elevance Health (ELV) Expanding AI Assistant Access And Adding Schulman To Board
Elevance Health recently expanded access to its AI-powered Virtual Assistant for about 22 million commercial members and announced that Amy Schulman, a senior healthcare executive and governance expert, will join its board and sit on the Audit and Finance Committees in January 2026. Together, these moves highlight Elevance Health’s push to blend digital-first member support with strengthened board oversight in healthcare innovation and regulatory strategy. We’ll now examine how the broader...
12 Days of Regulatory Insights: Day 6 – Sports Wagering, Player Proposition Bets, and Prediction Market Battles
In this episode of our special 12 Days of Regulatory Insights podcast series, Stephen Piepgrass is joined by Cole White from our RISE Practice Group's
The New WHO Pandemic Treaty and Global Health Governance: Incorporating Common but Differentiated Responsibilities into PABS - Georgetown Journal of International Affairs
On May 20, 2025, the World Health Assembly unanimously adopted the World Health Organization (WHO) Pandemic Agreement, an international treaty designed to strengthen pandemic prevention, preparedness, and response. The product of three years of arduous negotiations, the treaty marks a new era of global cooperation in public health. However, core aspects of the agreement remain unresolved—notably the Pathogen Access and Benefit-Sharing (PABS) System, which is intended to ensure equitable access to pandemic-related materials and benefits. To support the successful implementation of the WHO Pandemic Agreement, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Introduction For the first time, an international treaty has enshrined the principle of “One Health,” the compelling idea that the health of animals, humans, and the environment all contribute to pandemic risks. SARS (2003), H1N1 (2009–10), Ebola (2014–16), and COVID-19 all emerged through zoonotic spillover from animal hosts—respectively, civets, hogs, and bats. Together, they underscore the need for a coordinated, cross-sectoral approach. The Pandemic Agreement responds to this call, requiring state parties to acknowledge the ecological interplay and commit to a comprehensive “One Health” strategy. Specifically, Article 5 charges governments to address “the drivers of pandemics and the emergence and re-emergence of infectious disease at the human-animal-environment interface,” including wild animal markets, deforestation, and antibiotic overuse. Yet the effectiveness of this “One Health” vision depends equally on the free flow of scientific information and data among countries and institutions. Just as environmental and animal health factors have been neglected in past global frameworks, so too has data sharing been marginalized, despite its centrality to timely detection and response. The Pandemic Agreement takes an important step by requiring governments to enhance data collection and cooperate with the World Health Organization (WHO). However, these provisions will remain aspirational without a robust Pathogen Access and Benefit-Sharing (PABS) annex. The PABS system will determine whether countries and researchers can rapidly exchange pathogen samples and genetic data while ensuring equitable access to resulting research and development, including diagnostics, therapeutics, and vaccines. Without such mechanisms, the treaty’s promise to operationalize “One Health” and strengthen global preparedness will risk becoming largely symbolic, echoing earlier failures to translate shared principles into coordinated action. Equity Concerns When the 2025 Health Assembly adopted the Pandemic Agreement, it left the difficult question of access to pathogens and the sharing of resulting benefits to be addressed in a separate agreement. Negotiations on this separate agreement, PABS, are now underway in Geneva. Yet governments remain divided over fundamental questions of equity between the countries that primarily contribute to the system and those that primarily draw from it—and consequently benefit. For example, wildlife in countries bordering the equator is likely to produce PABS materials, but companies in Europe are likely to use them to develop lucrative products. The most likely contributor countries are likely to be those biodiverse countries around the equator, such as Brazil, the Democratic Republic of the Congo, and Indonesia, where the number of human-mammalian viral host interactions is large. Conversely, countries most likely to benefit from this material are those with the technology, investors, and infrastructure to capitalize on genomic data, such as the United States, EU member states, and Japan. This imbalance reflects a broader pattern seen in prior international frameworks. Now, as in the past, the wealthiest countries in the world (a useful heuristic is membership of the Organisation for Economic Co-operation and Development (OECD)) disproportionately benefit from systems in which pathogens and genomic sequencing data are contributed to a common source. Under the International Agreement on Plant Genetic Resources for Food and Agriculture (the “Plant Treaty” or “Seed Treaty”) and the Pandemic Influenza Preparedness (PIP) Framework, companies from Europe and North America disproportionately withdraw biological samples and data for development into lucrative medical products. Their governments and companies have both statutory and contractual claims to the products that those companies correspondingly produce. PABS appears poised to follow the same pattern. The text calls for strong language on access to pathogens and associated data, but the corresponding benefits that should flow to poorer countries are couched in equivocal or non-binding language. Common but Differentiated Responsibilities To address these inequities, the principle of “common but differentiated responsibilities” should be formally incorporated into the negotiating agenda of the PABS annex. Common but differentiated responsibilities are often a feature of climate change negotiations. The basic principle is that, even though all countries should reduce carbon emissions, governments that became rich and powerful through massive carbon emissions (e.g., France, the United Kingdom, the United States) should have a greater obligation to address the resulting crises. Applied to PABS, it would require that governments hosting and supporting companies developing lucrative products carry greater obligations toward the cost of running the PABS system; share benefits or final medical products; and transfer technology to help countries worldwide develop their own capacities to innovate and manufacture vaccines during an emergency. For example, an annex could mandate that any company based in an OECD country that withdraws PABS material would be obligated to donate the resulting diagnostics, therapeutics, or vaccines to the WHO during a public health emergency or pandemic. Questions remain about how robust those donations would be, but the principle is that they should deliver highly significant lifesaving benefits to be equitably shared. Theoretically, this approach mirrors the PIP Framework, in which companies withdrawing influenza samples are required to pay half of the operating costs. In practice, however, the framework has fallen short. The PIP Framework Secretariat has struggled to secure payments from companies, with companies often disagreeing over how much is owed. Additionally, without another pandemic influenza to test the strength of the agreement during a public health emergency, corporate compliance with sharing mechanisms remains unknown. Even if these limitations did not characterize the PIP Framework, partially paying for operating expenses does not address the inequity in access to genetic data and pathogen samples that left less developed countries last in line for COVID-19 vaccines (and, before them, H1N1). Common but differentiated responsibilities would go further, addressing governments’ legitimate grievances regarding information sharing. It would make withdrawals of PABS material and resulting products more transparent, building trust across the board. Enforcement and Enduring Success A key implication of this approach is that the governing mechanism of the PABS must have real enforcement authority. The WHO Pandemic Agreement delegates its core governance responsibilities to a Conference of the Parties (COP)—a governing body composed of one representative from each participating government, similar to those established under the UN Framework Convention on Climate Change and the WHO Framework Convention on Tobacco Control. The proposed WHO Pandemic Agreement COP is charged with oversight functions but ultimately possesses no real authority to compel a government to take any action it does not wish to take. The text does not give the COP the ability to, for example, sanction a party that does not comply with either textual obligations or PABS provisions. In other words, there are no effective mechanisms in place to ensure compliance. Perhaps just as significant, establishing a meaningful enforcement mechanism within the PABS system would strengthen the WHO’s credibility and its ability to ensure compliance across global health governance. By setting a precedent for accountability, such a mechanism could enhance the organization’s authority not only within the Pandemic Agreement but also in enforcing the revised International Health Regulations and other frameworks for public health emergencies. Conclusion The PABS annex can—and should—be different. It should establish clear responsibilities for funding as well as for sharing the diagnostics, therapeutics, and vaccines that result from contributions to the system. The system, in turn, must include a dedicated body empowered to hold governments and the corporations they sponsor accountable for their responsibilities before, during, and after pandemics. Doing so would restore trust in the broader agreement, which was eroded as commitments were repeatedly diluted while parties scrambled to meet their own self-imposed deadlines during the Pandemic Agreement negotiations. A robust PABS Annex would cement a grand social bargain. Wealthier countries and their corporations would gain unimpeded access to scientific information essential for developing and manufacturing lifesaving medical products. As such, they would stand to gain considerable economic benefit. Yet that privilege must be matched with responsibility. The grand bargain must include not only the right to innovate, but also the duty to ensure that innovation serves all. As medical products are developed and produced through collective contributions, every person must have equal access. All human beings deserve an equitable chance to survive—to save their own life, the lives of their families, and the well-being of their communities. … Sam Halabi, JD, MPhil, is the Bette Jacobs Endowed Professor at Georgetown University’s School of Health and the Director of the Center for Transformational Health Law at Georgetown Law. He serves as the co-lead for the WHO’s Working Group on Regulatory Consideration on AI and Health’s training workstream. He earned his JD from Harvard, his MPhil from Oxford, and undergraduate degrees from Kansas State University. Lawrence Gostin, LLD (Hon.), JD, BA, is University Distinguished Professor and Founding Director and Timothy and Linda O’Neill Professor of the O’Neill Institute for National and Global Health Law. He is the author of Global Health Security: A Blueprint for the Future (Harvard University Press, 2021); Global Health Law (Harvard University Press, 2014); Public Health Law: Power, Duty, Restraint (University of California Press, 3rd ed., 2016); Public Health Law and Ethics: A Reader (University of California Press, 3rd ed., 2018); Law and the Health System (Foundation Press, 2014); Principles of Mental Health Law & Practice (Oxford University Press, 2010). He also directs the WHO Collaborating Center at Georgetown University. Image Credit: United States Mission Geneva, CC BY 2.0, via Wikimedia Commons
Trump voices concern over Europe's political direction
Ties between the US and the EU are under pressure as Donald Trump questions Europe's trajectory and Brussels defends its recent regulatory decisions.
Conservative Project at Supreme Court Meets Trump’s Push to Oust Officials
President Trump has repeatedly ousted leaders of independent agencies despite federal laws meant to shield those regulators from politics.
Netflix to buy Warner Bros. and HBO Max
If approved by Trump administration regulators, the deal would lead to a new entertainment and technology behemoth.
Battle for sports betting market heats up as Polymarket announces return to the U.S.
The prediction market giant rolls out mobile platform almost four years after regulators banned it from the U.S.
Famenity's Brain Factor-7® Sets New Benchmark for Clinically Validated Cognitive-Health Solutions
SEOUL, South Korea, December 04, 2025--Famenity's BF-7® gains global attention as a cognitive-health ingredient backed by more than 12 human studies and major regulatory approvals.
A dozen former FDA commissioners condemn plan to tighten vaccine approvals
In a New England Journal of Medicine article, the former FDA commissioners wrote they were “deeply concerned” by the top vaccine regulator’s approach to raising the bar for approvals.
AT&T commits to ending DEI programs
US wireless carrier AT&T said in a letter to the US telecoms regulator that it had committed to ending diversity, equity and inclusion programs, a move that comes as it seeks approval from the Trump administration to buy wireless spectrum assets.
States Step Up to Regulate Digital Asset ‘Business Activity’ Within Their Borders
As Congress and federal financial regulators work to expand the legal playing field for crypto trading and transactions, states are stepping in regulate
AMPS Achieves HITRUST e1 Certification, Solidifying Commitment to Data Security in Healthcare
PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- AMPS, a healthcare technology solutions company serving self-insured employer groups, payors, healthcare brokers and consultants, and third-party administrators, announced today that its enterprise systems have earned HITRUST e1 Assessment Certification for cybersecurity and information protection. The HITRUST e1 Certification demonstrates that AMPS has met requirements defined by leading cybersecurity and regulatory frameworks, confirming that foundati
Business Trades Support Bank Capital Rule Reform to Boost Economic Growth
“Now is the time to modernize our capital framework to unleash economic growth for American businesses and consumers across the country.” WASHINGTON, D.C. — A coalition of leading business trade organizations urged prudential regulators to examine and modernize large bank capital requirements to ensure they support consumers, businesses, and the…
Intensifying Regulatory Pressures Force Seismic Shift in Health Plan Concerns for 2026 According to HealthEdge Research
BOSTON, December 02, 2025--As healthcare organizations navigate an increasingly complex policy environment, 85% of health plan executives say regulatory pressures are impacting their costs and margins, according to new research published today by HealthEdge®. The report, "The Great Rebalancing: Inside the New Realities Shaping Health Plan Performance," identifies the top challenges in the payer market, how they are evolving, and strategies health plans are deploying to overcome them.
Regnology Completes Acquisition of Wolters Kluwer’s Finance, Risk & Regulatory Reporting Business
FRANKFURT, Germany, December 01, 2025--Regnology has completed the acquisition of Wolters Kluwer’s FRR business, marking a major milestone in regulatory technology leadership.